A study to investigate immune challenge induced skin reactions with SAR445399, canakinumab and spesolimab compared with placebo, in healthy participants aged 18 to 55 years

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511241-19-00

Acronym

PDY18058

Enrollment

125

Registered

2024-07-18

Start date

2024-07-19

Completion date

2024-12-05

Last updated

2024-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immuun system diseases

None listed

Sex/Gender

All

Age

18 Years to 64 Years

Netherlands

None listed

Source: EU CTIS · Data processed: Feb 4, 2026